Evolent Health (EVH) director receives 23,137 RSUs in equity award

Rhea-AI Filing Summary

Evolent Health, Inc. reported that director Ms. Smith received an equity award of 23,137 restricted stock units of Class A common stock on 01/02/2026. The units were granted at a price of $0 under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan and are shown as directly owned after the transaction.

The restricted stock units vest on the earlier of January 2, 2027 or the date of the company’s 2026 annual meeting, as long as she continues in service through the vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Jill D.

(Last) (First) (Middle)

C/O EVOLENT HEALTH, INC.

1812 N. MOORE ST., STE. 1705

(Street)

ARLINGTON VA 22209

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Evolent Health, Inc. [ EVH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock(1)	01/02/2026		A		23,137(2)	A	$0	23,137	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units granted to Ms. Smith pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

2. Securities vest on the earlier of January 2, 2027, and the date of the Company's 2026 annual meeting, subject to the reporting person's continued service on the vesting date.

Remarks:

	/s/ Jonathan Weinberg, Attorney-in-fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Evolent Health (EVH) disclose in this filing?

The filing shows that director Ms. Smith was granted 23,137 restricted stock units of Evolent Health Class A common stock on 01/02/2026.

What type of Evolent Health (EVH) security was granted to the director?

The award consists of restricted stock units that will settle in shares of Evolent Health Class A common stock.

When do the granted Evolent Health (EVH) restricted stock units vest?

The securities vest on the earlier of January 2, 2027 and the date of Evolent Health’s 2026 annual meeting, subject to continued service.

What was the reported price for the Evolent Health (EVH) restricted stock unit grant?

The Form 4 indicates a price of $0 for the grant of 23,137 restricted stock units to Ms. Smith.

How many Evolent Health (EVH) shares does the director beneficially own after this transaction?

After the reported transaction, the form lists 23,137 Evolent Health Class A common shares as directly beneficially owned.

Under which plan were the Evolent Health (EVH) restricted stock units granted?

The restricted stock units were granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.